AstraZeneca Rejects Pfizer Bid With ‘No Hesitation’
Pfizer Inc. (NYSE:PFE) confirmed earlier this week that it was trying to bring AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN) back to the negotiating table after its previous attempt to buy the company fell through this past January. The proposal reportedly valued AstraZeneca at $100 million, roughly its current market cap, but it would have relocated AstraZeneca to the UK for tax purposes and contained the same mix of cash/shares, both provisions that the AstraZeneca board objected to last time.
This content is exclusively for paying members of ValueWalk Premium Gain Exclusive Access to the Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with ValueWalk Premium Get Started Now with a FREE 7-Day Trial 🔻 If you are a current ValueWalk Premium member and are having an account error please clear cache and cookies. If that does not work, email [email protected] or click Chat.
|
